Flawed Study Groups Failed and Successful Alzheimer Drugs Together
This new analysis of Alzheimer's drugs is such a good example of why we can't make any headway as a society. There is probably a good debate to be had on whether the risks and costs of the two approved beta amyloid drugs, Leqembi and Kisunla, are justified by their benefits. This is not that. The @cochranecollab authors took the data from the 15 Alzheimer's drugs that failed in clinical trials but had the same basic medicine (antibodies against beta amyloid) as the two that succeeded and lumped them all together. You don't need statistics to know how silly this is. If you lumped the two fastest sprinters in the world with 15 people who never qualified for a race you'd conclude all people are slow. Having good debates requires both sides to put forward a thoughtful argument that takes into account the view of the other side. This is not that. $LLY. And seriously, @ProfRobHoward, how is this wellconstructured?
Scientists Propose Abandoning GLP‑1 as Obesity Target
Researchers behind GLP-1 obesity drugs advance new approach: Drop GLP-1 as a target https://t.co/ADzYb2Zqal via @statnews
Personal Loss Exposes Danger of Dismissing Cancer Breakthroughs
Hype is bad. That includes calling an unprecedented advance in cancer treatment hype when it is not. Don’t think about the knee jerk comment this tweet is replying to. Think about this man’s wife getting three vacations.
CDC Vaccine Panel Rules Target Lawsuit, Boost Kennedy Allies
New rules for CDC vaccine panel aim to address lawsuit, empower Kennedy’s allies https://t.co/miSg4oOYSu via @statnews
Controversial Drugs Once Feared, Now Offer Hope
A decade ago, these drugs tore apart the FDA. Today, they might be some patients’ best hope Another wonderful piece from @Jasonmmast https://t.co/zOvLrdAPKi via @statnews
Bad Peptide Manufacturing, Not the Peptides, Drives Danger
Just because peptides are manufactured badly and contain toxins does not mean that they will be safe and effective if manufactured well. Seriously, just eat whole foods, exercise, and maybe take a damn statin.
UnitedHealth's $3 B AI Bet Promises Patient Benefits
UnitedHealth Group + AI +Polk winner @caseymross = A must read. $UNH is making a $3 billion bet on AI. What does it mean for patients? https://t.co/irkyZi8Wj6
Trump Proposes $5 B NIH Cut; Congress Unlikely to Approve
NIH would get $5 billion cut under Trump’s 2027 budget, but Congress unlikely to go along https://t.co/PPQbrSBwi0 via @statnews
Evidence‑Heavy Statins Still Outpace Unproven Peptides
There is a fascinating op-ed piece in STAT from a doctor whose patient rejected a statin -- one of the most tested drug classes in existence -- but chose to take an untested peptide for cardiovascular risk. "My patient is intelligent,...
HHS Transfers Missed the Mark for IHS Staffing
HHS Officials’ Year in Purgatory Is Ending The Indian Health Service needs more clinical workers. The federal health officials being transferred to the agency don’t fit that bill. @KatherineJWu reports: https://t.co/kb9mVkY3S7
Elaine Chen Showcases Biotech Deals and Mind‑bending Insights
I'd like to draw your attention to my fantastic @statnews colleague @elaineywchen. She led the way our obesity drug coverage, is a host on our podcast, and writes our biotech newsletter most days. Today has two big examples of the...
US VCs Embed in Chinese Labs, Courting Scientists Early
U.S. venture capital firms are no longer waiting for Chinese biotech assets to surface before investing in them — they’re moving upstream, embedding themselves inside labs and courting scientists before they publish their research https://t.co/7kOlGh0sbu
Tech Experts Overestimate Their Grasp of Cancer Biology
As someone who has covered cancer drug development for 25 years, one of the few things I am sure of is that the odds of technology folks thinking they understand biology are much higher than the odds they actually do.
NIH Foreign‑collab Restrictions Affect 25% of U.S. Scientists
Survey shows the NIH's restrictions on foreign research partnerships significantly impacted 1 in 4 U.S. scientists https://t.co/YVbTQ4tveG
Remembering Tracy Kidder: ‘Soul’ Inspiration and Paul Farmer Profile
A legend. ‘Soul’ meant everything to me as a young journalist, but it’s his book-length profile of Paul Farmer that I love most, even with its flaws. Tracy Kidder, Author of ‘The Soul of a New Machine,’ Dies at 80 ...
